Atossa Therapeutics (ATOS) Status update summary

Innovations in breast cancer clinical trials

• Traditional drug development is slow and inefficient, with excessive procedural steps and outdated statistical models.

• Platform trials like I-SPY enable rapid evaluation of multiple therapies, using adaptive Bayesian designs to learn as trials progress.

• Centralized IRB and FDA processes now allow new trial arms to launch within a month, enrolling patients at scale.

• I-SPY has screened nearly 6,000 patients, enrolled 3,800, and generated over 150 publications, validating early biomarkers and improving response rates.

• The approach emphasizes early endpoints and individualized treatment, aiming to accelerate knowledge cycles from 17 to 3 years.

Challenges and advances in endocrine therapy

• Endocrine therapies are often poorly tolerated, leading to high discontinuation rates; improving tolerability is a key goal.

• Endoxifen, an active metabolite of tamoxifen, shows high efficacy and superior tolerability compared to standard therapies.

• Trials like RECAST DCIS and I-SPY are testing endoxifen in various settings, with promising patient adherence and outcomes.

• Combination therapies, such as endoxifen with abemaciclib or elagolix, are being explored to enhance efficacy and reduce side effects.

• Early markers like Ki-67 reduction and MRI-based assessments are used to guide therapy and predict outcomes.

Regulatory and trial design considerations

• There is a push for the FDA to accept early surrogate endpoints and adaptive trial designs to speed approvals.

• Standardized measurement of residual cancer burden and early response is critical for trial success and regulatory acceptance.

• Seamless phase III trials and community engagement are strategies to align with regulatory expectations.

• Advocates and investigators are working to bring less toxic, more effective therapies to market faster, focusing on patient quality of life.